Charles P. O’brien

Charles P. O’brien's AcademicInfluence.com Rankings

Charles P. O’brien

Philosophy

#2899

World Rank

#4808

Historical Rank

Logic

#840

World Rank

#1392

Historical Rank

philosophy Degrees

Charles P. O’brien

Biology

#3449

World Rank

#5276

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Charles P. O’brien's Degrees

Doctorate Medicine University of Pennsylvania

Why Is Charles P. O’brien Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Charles P. O’brien's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

An Improved Diagnostic Evaluation Instrument for Substance Abuse Patients: The Addiction Severity Index (1980) (3118)
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. (2000) (2337)
New Data from the Addiction Severity Index Reliability and Validity in Three Centers (1985) (1529)
Limbic activation during cue-induced cocaine craving. (1999) (1520)
Naltrexone in the treatment of alcohol dependence. (1992) (1020)
DSM-5 criteria for substance use disorders: recommendations and rationale. (2013) (1008)
Predicting response to alcohol and drug abuse treatments. Role of psychiatric severity. (1983) (825)
Therapist success and its determinants. (1985) (754)
An international consensus for assessing internet gaming disorder using the new DSM-5 approach. (2014) (748)
Conditioning factors in drug abuse: can they explain compulsion? (1998) (654)
Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients (2002) (582)
A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients (2003) (523)
Myths about the treatment of addiction (1996) (521)
Internet gaming disorder and the DSM-5. (2013) (494)
Classical Conditioning in Drug‐Dependent Humans a (1992) (482)
Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. (1993) (473)
Naltrexone and alcohol dependence. Role of subject compliance. (1997) (425)
A New Measure of Substance Abuse Treatment Initial Studies of the Treatment Services Review (1992) (419)
Benzodiazepine use, abuse, and dependence. (2005) (411)
A range of research-based pharmacotherapies for addiction. (1997) (394)
Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. (1994) (390)
Sociopathy and psychotherapy outcome. (1985) (384)
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence (2005) (375)
Psychotherapy for opiate addicts. Does it help? (1983) (371)
Anticraving medications for relapse prevention: a possible new class of psychoactive medications. (2005) (361)
Limbic Activation to Cigarette Smoking Cues Independent of Nicotine Withdrawal: A Perfusion fMRI Study (2007) (361)
Cue reactivity and cue reactivity interventions in drug dependence. (1993) (349)
Prelude to Passion: Limbic Activation by “Unseen” Drug and Sexual Cues (2008) (348)
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. (2003) (330)
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. (2006) (329)
The Status of Disulfiram: A Half of a Century Later (2006) (329)
Effect of naltrexone on alcohol "high" in alcoholics. (1995) (318)
Conditioned responses to cocaine-related stimuli in cocaine abuse patients (2005) (304)
Integrating systemic cue exposure with standard treatment in recovering drug dependent patients. (1990) (299)
A pilot trial of topiramate for the treatment of cocaine dependence. (2004) (283)
Cocaine dependence: a disease of the brain's reward centers. (2001) (276)
Comparing attentional bias to smoking cues in current smokers, former smokers, and non-smokers using a dot-probe task. (2002) (271)
Three decision-making tasks in cocaine-dependent patients: do they measure the same construct? (2001) (271)
Classically conditioned responses in opioid and cocaine dependence: a role in relapse? (1988) (263)
Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. (1996) (257)
Issues for DSM-V: should obesity be included as a brain disorder? (2007) (257)
Addiction and dependence in DSM-V. (2011) (254)
Neurobiology of addiction: treatment and public policy ramifications (2005) (253)
Comparing levels of cocaine cue reactivity in male and female outpatients. (1999) (253)
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. (2016) (248)
Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. (1986) (247)
Increased Effectiveness of Substance Abuse Treatment: A Prospective Study of Patient‐Treatment “Matching” (1983) (240)
Pharmacogenetic approaches to the treatment of alcohol addiction (2011) (239)
Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence (1997) (225)
Problem-service 'matching' in addiction treatment. A prospective study in 4 programs. (1997) (225)
Critical assessment of how to study addiction and its treatment: human and non-human animal models. (2005) (216)
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. (2006) (216)
What's in a word? Addiction versus dependence in DSM-V. (2006) (215)
Experimental analysis of conditioning factors in human narcotic addiction. (1975) (213)
Naltrexone pharmacotherapy for opioid dependent federal probationers. (1997) (210)
Is treatment for substance abuse effective? (1982) (210)
Predicting treatment response to naltrexone: the influence of craving and family history. (2001) (210)
Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. (1989) (208)
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. (2010) (205)
Current status of co-occurring mood and substance use disorders: a new therapeutic target. (2015) (205)
Development of psychiatric illness in drug abusers. Possible role of drug preference. (1979) (204)
Conditioned narcotic withdrawal in humans. (1977) (201)
Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. (2013) (201)
Predicting the outcome of psychotherapy. findings of the Penn Psychotherapy Project. (1980) (199)
Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. (2008) (197)
Naltrexone in the treatment of alcoholism: a clinical review. (1996) (195)
Psychotherapy in community methadone programs: a validation study. (1995) (190)
Severity of psychiatric symptoms as a predictor of benefits from psychotherapy: the Veterans Administration-Penn study. (1984) (186)
Internet Gaming Disorder in the DSM-5 (2015) (185)
Effect of smoking cues and cigarette availability on craving and smoking behavior. (1995) (178)
Can induced moods trigger drug-related responses in opiate abuse patients? (1994) (174)
A learning model of addiction. (1992) (171)
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. (2003) (171)
The Status of Naltrexone in the Treatment of Alcohol Dependence: Specific Effects on Heavy Drinking (2006) (169)
Effects of varenicline on smoking cue–triggered neural and craving responses. (2011) (153)
Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. (1975) (150)
A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. (1998) (148)
Conditioned craving and arousal in cocaine addiction: a preliminary report. (1988) (147)
Addiction Severity Index (2012) (146)
The CAGE questionnaire for detection of alcoholism: a remarkably useful but simple tool. (2008) (144)
Plasma testosterone level and sexual behavior of couples (1978) (144)
A genetic association study of the mu opioid receptor and severe opioid dependence (2003) (138)
An Overview of and Rationale for Changes Proposed for Pathological Gambling in DSM-5 (2014) (137)
Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. (2001) (136)
Naltrexone in the treatment of alcoholism: predicting response to naltrexone. (1995) (136)
Desipramine treatment of cocaine dependence in methadone-maintained patients. (1992) (134)
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action (2004) (131)
HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS (2002) (125)
Are the “Addiction‐related” Problems of Substance Abusers Really Related? (1981) (123)
Effectiveness and Costs of Inpatient versus Day Hospital Cocaine Rehabilitation (1994) (120)
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) (1999) (119)
Relationship of perceived competencies, perceived social support, and gender to substance use in young adolescents. (1997) (118)
Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. (2001) (117)
Evidence-based treatments of addiction (2008) (115)
Alcohol and drug abuse treatment in three different populations: is there improvement and is it predictable? (1986) (114)
Alcohol potentiates hepatitis C virus replicon expression (2003) (113)
Group counseling versus individualized relapse prevention aftercare following intensive outpatient treatment for cocaine dependence: initial results. (1997) (111)
Private substance abuse treatments: are some programs more effective than others? (1993) (111)
Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. (1986) (109)
Treating and preventing adolescent mental health disorders: What We Know and What We Don't Know. A Research Agenda for Improving the Mental Health of Our Youth (2005) (109)
Risk factors for needle sharing among methadone-treated patients. (1991) (107)
Can independent judges recognize different psychotherapies? An experience with manual-guided therapies. (1982) (106)
Pharmacological and behavioral treatments of cocaine dependence: controlled studies. (1988) (105)
Drug Treatment as HIV Prevention: A Research Update (2010) (104)
Crack cocaine abuse: an epidemic with many public health consequences. (1996) (104)
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. (2015) (103)
The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. (2009) (103)
Twelve-month follow-up of psychotherapy for opiate dependence. (1987) (102)
The Relation of Plasma Androgen Levels to Sexual Behaviors and Attitudes of Women1 (1982) (101)
Psychotherapy for opiate addicts. (1983) (101)
Effect of random versus nonrandom assignment in a comparison of inpatient and day hospital rehabilitation for male alcoholics. (1995) (100)
A Double-Blind, Placebo-Controlled Pilot Trial of Quetiapine for the Treatment of Type A and Type B Alcoholism (2007) (99)
Nipping Cue Reactivity in the Bud: Baclofen Prevents Limbic Activation Elicited by Subliminal Drug Cues (2014) (98)
Naltrexone for heroin dependence treatment in St. Petersburg, Russia. (2004) (97)
DAT Genotype Modulates Brain and Behavioral Responses Elicited by Cigarette Cues (2009) (96)
Predictors of participation in aftercare sessions and self-help groups following completion of intensive outpatient treatment for substance abuse. (1998) (91)
A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. (2013) (90)
Naltrexone and the Treatment of Alcohol-Dependence: Initial Observations (1990) (90)
Misuse and abuse of diazepam: an increasingly common medical problem. (1975) (90)
Relationships among physiological and self-report responses produced by cocaine-related cues. (1997) (90)
Treatment of patients with substance use disorders (2006) (90)
Extinguishing conditioned responses during opiate dependence treatment turning laboratory findings into clinical procedures. (1986) (88)
Mental effects of high-dosage levodopa. (1971) (87)
Retrospective study: influence of menstrual cycle on cue-induced cigarette craving. (2004) (87)
Improving Naltrexone Response (2000) (86)
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. (2006) (86)
Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach (2001) (84)
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. (2008) (84)
A pilot trial of olanzapine for the treatment of cocaine dependence. (2003) (84)
Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. (2008) (83)
Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. (2008) (82)
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. (2001) (82)
Glutamatergic Agents for Cocaine Dependence (2003) (81)
Role of conditioning factors in the development of drug dependence. (1986) (81)
Group vs individual psychotherapy with schizophrenics. A controlled outcome study. (1972) (81)
Substance Use Disorders in the U.S. Armed Forces (2013) (80)
A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. (2006) (79)
Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. (1997) (78)
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. (2006) (78)
Clinical experience with naltrexone. (1975) (74)
Caffeine: behavioral effects of withdrawal and related issues. (2002) (73)
Effect of naltrexone on food intake, hunger, and satiety in obese men (1987) (73)
Research advances in the understanding and treatment of addiction. (2003) (72)
Naltrexone in the treatment of alcoholism. (1997) (72)
Neural responses to subliminally presented cannabis and other emotionally evocative cues in cannabis-dependent individuals (2014) (71)
Naltrexone: a clinical perspective. (1984) (71)
Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat. (1998) (70)
Continuing care for cocaine dependence: comprehensive 2-year outcomes. (1999) (69)
Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. (2018) (69)
Sexual problems of heroin addicts. (1974) (68)
Rational development of addiction pharmacotherapies: successes, failures, and prospects. (2012) (68)
Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. (2001) (67)
The Dopamine Receptor D2 (DRD2) SNP rs1076560 is Associated with Opioid Addiction (2014) (67)
Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. (1992) (66)
A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. (2015) (66)
REVIEW: Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone (2006) (66)
The effects of naltrexone on alcohol and cocaine use in dually addicted patients. (1999) (66)
Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. (1995) (65)
Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. (2012) (65)
Predictors of favorable outcome following naltrexone treatment. (1983) (64)
Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. (2002) (63)
Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. (2013) (63)
Detecting smoking following smoking cessation treatment. (2002) (63)
Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain. (2019) (63)
Mood states can elicit conditioned withdrawal and craving in opiate abuse patients. (1987) (62)
Association Between the Catechol-O-Methyltransferase Val158Met Polymorphism and Cocaine Dependence (2008) (61)
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. (2008) (60)
Coerced treatment for substance abuse problems detected through workplace urine surveillance: is it effective? (1996) (60)
Dopamine receptor partial agonists could address the duality of cocaine craving. (2000) (60)
Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. (1996) (58)
Psychotherapy and counseling for methadone-maintained opiate addicts: results of research studies. (1990) (57)
Amantadine may facilitate detoxification of cocaine addicts. (1992) (57)
Prognostic significance of antisocial personality disorder in cocaine-dependent patients entering continuing care. (2000) (57)
Mood state and recent cocaine use are not associated with levels of cocaine cue reactivity. (2000) (56)
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. (2008) (56)
Matching substance abuse patients to appropriate treatments: a conceptual and methodological approach. (1980) (56)
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. (2012) (56)
Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations. (2013) (56)
Treatment response in psychiatrically impaired drug abusers. (1981) (54)
Corrections and revised analyses for psychotherapy in methadone maintenance patients. (1990) (54)
Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. (2000) (54)
How effective is substance abuse treatment--compared to what? (1992) (53)
The addiction severity index in three different populations. (1984) (53)
Psychosocially enhanced treatment for cocaine-dependent mothers: evidence of efficacy. (2000) (53)
Extinction of conditioned responses in abstinent cocaine or opioid users. (1987) (53)
Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. (2002) (53)
A VBM study demonstrating ‘apparent’ effects of a single dose of medication on T1-weighted MRIs (2012) (52)
Under the influence? Drugs and the American work force. (1995) (51)
Developing treatments that address classical conditioning. (1993) (51)
Recent developments in the pharmacotherapy of substance abuse. (1996) (51)
Naltrexone for probationers and parolees. (2006) (51)
Desipramine Treatment for Cocaine Dependence: Role of Antisocial Personality Disorder (1994) (50)
The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat (2001) (50)
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations (2012) (48)
Carbamazepine treatment for cocaine dependence. (1995) (48)
Random versus nonrandom assignment in the evaluation of treatment for cocaine abusers. (1998) (48)
Gender differences in comorbidly depressed alcohol-dependent outpatients. (1997) (48)
Covariates of craving in actively drinking alcoholics. (2010) (46)
The relationship of plasma estradiol to sexual behavior in young women. (1978) (46)
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. (2012) (46)
Do caffeine‐containing analgesics promote dependence? A review and evaluation (2000) (45)
The effect of alcohol and smoking on testosterone function and aggression in chronic alcoholics. (1977) (45)
Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. (2008) (44)
Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study. (2011) (44)
Depression in veterans two years after Viet Nam. (1977) (44)
Psychiatric disorders in opioid-dependent patients. (1984) (44)
A randomized trial of oral naltrexone for treating opioid-dependent offenders. (2010) (43)
Effects of an appointment reminder call on patient show rates. (1995) (43)
Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence (2012) (43)
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence (2005) (43)
[Buprenorphine in the treatment of opiate dependence]. (1994) (43)
THE USE OF ANTIDEPRESSANTS WITH METHADONE IN DEPRESSED MAINTENANCE PATIENTS * (1982) (42)
Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction (2012) (42)
Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. (2004) (42)
Hormone secretion in methadone-dependent and abstinent patients. (1988) (42)
Naltrexone: a short-term treatment for opiate dependence. (1981) (41)
Types of conditioning found in drug-dependent humans. (1988) (41)
Extended‐release naltrexone modulates brain response to drug cues in abstinent heroin‐dependent patients (2014) (41)
Prevention of Eating Disorders (2005) (40)
Reward-related Brain Response and Craving Correlates of Marijuana Cue Exposure: A Preliminary Study in Treatment-seeking Marijuana-dependent Subjects (2013) (40)
Effects of contingent payment on compliance with a naltrexone regimen. (1979) (40)
Unreinforced self-injections: effects on rituals and outcome in heroin addicts. (1979) (39)
Naloxone can alter experimental pain and mood in humans (1981) (39)
CLINICAL PHARMACOLOGY OF NARCOTIC ANTAGONISTS * (1978) (39)
The impact of sex on brain responses to smoking cues: a perfusion fMRI study (2013) (38)
Conditioning of narcotic abstinence symptoms in human subjects. (1975) (38)
Cynthia ' s Dilemma : Consenting to Heroin Prescription (2017) (36)
A comparison of the effects of 6-β naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats (2002) (36)
A functional prodynorphin promoter polymorphism and opioid dependence (2005) (36)
Failure of ritanserin to block cocaine cue reactivity in humans. (1996) (36)
CONDITIONING MECHANISMS IN DRUG DEPENDENCE (1992) (35)
Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine (2013) (34)
Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. (1983) (34)
Behavioral therapies for substance abuse. (1985) (33)
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence (2015) (33)
Effect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the rat. (2002) (33)
Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. (2010) (33)
Increase in desipramine serum levels associated with methadone treatment. (1989) (33)
Psychiatric symptoms, risky behavior, and HIV infection. (1997) (33)
Conditioning in human opiate addicts (1976) (32)
Pretreatment source of income and response to methadone maintenance: a follow-up study. (1981) (32)
Treatment response and safety of ambulatory medical detoxication. (1988) (32)
Research on psychopathology and addiction: treatment implications. (1990) (31)
Laboratory exposure to cocaine cues does not increase cocaine use by outpatient subjects. (1998) (31)
Follow-up of Vietman veterans. I. Relapse to drug use after Vietnam service. (1980) (31)
Clinical Medications Development for Opiate Addiction: Focus on Nonopioids and Opioid Antagonists for the Amelioration of Opiate Withdrawal Symptoms and Relapse Prevention (1997) (30)
Opioid therapy in patients with chronic noncancer pain: diagnostic and clinical challenges. (2011) (30)
Cost‐effectiveness of extended release naltrexone to prevent relapse among criminal justice‐involved individuals with a history of opioid use disorder (2017) (29)
Griffiths et al.'s comments on the international consensus statement of internet gaming disorder: furthering consensus or hindering progress? (2016) (29)
Gender and psychiatric comorbidity: impact on clinical presentation of alcohol dependence. (2000) (29)
A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. (2001) (29)
Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. (2008) (29)
Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population (2005) (29)
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. (2009) (28)
Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. (2010) (28)
The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders (2012) (28)
Results of two levels of adjunctive treatment used with the nicotine patch. (1997) (27)
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence (2010) (27)
A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients. (2002) (27)
Treatment of alcoholism as a chronic disorder. (1994) (27)
Acute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study. (2012) (26)
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. (2015) (26)
The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. (2000) (26)
A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction. (1981) (26)
Assessment and extinction of conditioned withdrawal-like responses in an integrated treatment for opiate dependence. (1984) (26)
Open trials as a method of prioritizing medications for inclusion in controlled trials for cocaine dependence. (1999) (25)
Myxoid tumor of the uterus and right atrial myxomas. (1983) (25)
Overview: the treatment of drug dependence. (1994) (25)
A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. (2011) (24)
Psychological severity and response to alcoholism rehabilitation. (1981) (24)
Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues (2017) (24)
Naltrexone inhibits alcohol‐mediated enhancement of HIV infection of T lymphocytes (2006) (23)
Anticholinergic toxic psychosis in drug abusers treated with benztropine. (1974) (23)
Cocaine dependence: the challenge for pharmacotherapy (2002) (23)
Naltrexone for alcoholic adolescents. (1997) (23)
Clinical correlations with carbohydrate-deficient transferrin levels in women with alcoholism. (1998) (23)
Effects Of Use (1994) (23)
Conditioned tolerance in human opiate addicts (2005) (22)
ENDORPHIN LEVELS IN OPIOID‐DEPENDENT HUMAN SUBJECTS: A LONGITUDINAL STUDY * (1982) (22)
Absence of naloxone sensitivity in obese humans. (1982) (22)
Commentary on Tao et al. (2010): Internet addiction and DSM‐V (2010) (22)
Endogenous opioids in cerebrospinal fluid of opioid-dependent humans (1988) (22)
Nondependent monkeys self-administer hydromorphone. (1985) (22)
Reproductive Hormone Levels and Sexual Behaviors of Young Couples During the Menstrual Cycle (1977) (22)
Molecular Genetics and New Medication Strategies for Opioid Addiction. (2018) (21)
A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. (2003) (21)
Psychiatric symptoms, high risk behaviors and HIV positivity among methadone patients. (1990) (21)
Group therapy for schizophrenia: a practical approach. (1975) (21)
6-β-Naltrexol Reduces Alcohol Consumption in Rats (2000) (20)
Neuronal calcium sensor-1 and cocaine addiction: A genetic association study in African-Americans and European Americans (2012) (20)
Classical conditioning in opiate dependence. (1984) (20)
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? (2018) (20)
Does modafinil produce euphoria? (2006) (20)
GENETIC STUDY: Analysis of variations in the tryptophan hydroxylase‐2 (TPH2) gene in cocaine dependence (2006) (20)
Conditioned drug responses to naturalistic stimuli. (1979) (19)
Conditioning factors may help to understand and prevent relapse in patients who are recovering from drug dependence. (1991) (19)
Neuroplasticity in addictive disorders (2009) (19)
Measurement and extinction of conditioned withdrawal-like responses in opiate-dependent patients. (1984) (19)
Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment. (2017) (18)
Treatment of Drug and Alcohol Abuse. (1984) (18)
Novel exonic μ‐opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence (2005) (18)
Position statement on methadone maintenance treatment. (1994) (18)
Identifying Risk Factors for Marijuana Use Among Veterans Affairs Patients (2010) (18)
The mosaic of addiction. (2004) (18)
Addressing psychiatric comorbidity. (1991) (18)
Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. (2018) (18)
PSYCHOTHERAPY FOR OPIATE ADDICTION: SOME PRELIMINARY RESULTS (1981) (17)
Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids. (2013) (17)
Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers. (1993) (17)
Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain (2018) (17)
Risk for alcoholism and methadone treatment. A longitudinal study. (1980) (16)
Under the Influence (1994) (16)
The DSM-5 field trials and reliability of alcohol use disorder. (2013) (16)
Moving internet gaming disorder forward: A reply. (2014) (16)
Defining Depression and Bipolar Disorder (2005) (16)
Classically conditioned phenomena in human opiate addiction. (1981) (16)
Prospects for a genomic approach to the treatment of alcoholism. (2008) (16)
A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence. (2014) (16)
Evaluation of treatment for cocaine dependence. (1989) (15)
Update on Methadone Maintenance (1986) (15)
Progress in the science of addiction. (1997) (15)
The disabling nature of comorbid depression among older DUI recipients. (1999) (15)
Benzodiazepines: Revisiting Clinical Issues in Treating Anxiety Disorders. (2005) (15)
Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence. (2009) (14)
A 50-year-old woman addicted to heroin: review of treatment of heroin addiction. (2008) (14)
The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder (2020) (14)
Improving detection of adverse effects of marketed drugs. (2007) (14)
The Relationship of Plasma Estradiol Level to Sexual Behavior in Young Women (1978) (14)
The NMDA Receptor Partial Agonist, 1-Aminocyclopropanecarboxylic Acid (ACPC), Reduces Ethanol Consumption in the Rat (1999) (14)
Focal networks and HIV risk among African-American male intravenous drug users. (1995) (14)
Psychotropic agents in opiate addiction: a brief review. (1980) (14)
Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence (2008) (13)
The impact of Vietnam service on heroin-addicted veterans. (1979) (13)
Increasing the likelihood that consent is informed. (1979) (13)
110 NEUROIMAGING OF COCAINE CRAVING STATES : CESSATION , STIMULANT ADMINISTRATION , AND DRUG CUE PARADIGMS (2002) (13)
The Addiction Severity Index in clinical efficacy trials of medications for cocaine dependence. (1997) (13)
Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients. (2009) (12)
Enhancing the effectiveness of methadone using psychotherapeutic interventions. (1995) (12)
Depression in treated narcotic addicts, ex-addicts, nonaddicts, and suicide attempters: validation of a very Brief Depression Scale. (1979) (12)
Progress in understanding the conditioning aspects of drug dependence. (1988) (11)
Are there minimum conditions necessary for methadone maintenance to reduce intravenous drug use and AIDS risk behaviors? (1991) (11)
Use of naltrexone to extinguish opioid-conditioned responses. (1984) (11)
Clinical Pharmacokinetics of Lofexidine, the α 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis (2008) (11)
Defining eating disorders. (2005) (11)
The opioids: abuse liability and treatments for dependence. (1990) (11)
Carbohydrate-deficient transferrin: an investigative biochemical marker of heavy alcohol consumption. (1997) (11)
Alcohol suppresses IL-2-induced CC chemokine production by natural killer cells. (2005) (10)
Integrating Behavioral Therapies with Medications in the Treatment of Drug Dependence. Proceedings of a meeting. June 10-11, 1993. (1995) (10)
Certain types of substance abuse patients do better in certain kinds of treatments: evidence for patient-program matching. (1981) (10)
Treatment of behavioral and psychiatric problems associated with opiate dependence. (1984) (10)
Increased effectiveness of drug abuse treatment from patient-program matching. (1983) (10)
The Research, Policy, and Practice Context for Delivery of Evidence-Based Mental Health Treatments for Adolescents: A Systems Perspective (2005) (10)
Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction. (1979) (9)
Responding to drug-related stimuli in humans as a function of drug-use history. (1991) (9)
Effect of the research process on human sexual behavior. (1981) (9)
Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. (2018) (9)
Limitations of the use of the MP-RAGE to identify neural changes in the brain: recent cigarette smoking alters gray matter indices in the striatum (2015) (9)
Opiate receptors, neuropeptides in CNS and CSF of two Macaca species with different responsiveness to opiates. (1986) (9)
It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
Addiction treatment in Russia (2010) (9)
Extended-release naltrexone for opioid relapse prevention among opioid-dependent, criminal justice-involved adults (2015) (9)
Current research in the treatment of alcoholism in liver transplant recipients. (1997) (9)
Long-term consequences of opiate dependence. (1981) (9)
Interaction between thioridazine and naltrexone. (1987) (8)
Cynomolgus monkeys do not develop tolerance to opioids. (1983) (8)
Treatment of Substance-Related Disorders (2009) (8)
The relationship of sexual adjustment and related sexual behaviors and attitudes to marital adjustment (1982) (8)
Biofeedback-mediated relaxation in narcotic addicts (1978) (8)
Evaluation for withdrawal symptoms following chronic zomepirac administration. (1980) (8)
Day hospital vs. inpatient rehabilitation of cocaine abusers: an interim report. (1993) (8)
A case report of naltrexone for alcoholism in a liver transplant recipient: side effects and safety. (2004) (8)
Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence (2009) (8)
Depot naltrexone as relapse prevention for opioid-dependent parolees (2015) (8)
TREATMENT OF MIXED ABUSERS IN METHADONE MAINTENANCE: ROLE OF PSYCHIATRIC FACTORS * (1982) (8)
Wavelet-transformed temporal cerebral blood flow signals during attempted inhibition of cue-induced cocaine craving distinguish prognostic phenotypes. (2013) (7)
Defining Anxiety Disorders (2005) (7)
6-beta-naltrexol reduces alcohol consumption in rats. (2000) (7)
Concurrent Cocaine Withdrawal Alters Alcohol Withdrawal Symptoms (2002) (7)
Some Observations Concerning the Hypothalamic Regulation of Growth and of Food Intake (1964) (7)
Is drug abuse treatment effective? (1982) (7)
A cross-sectional study of attitudes about the use of genetic testing for clinical care among patients with an alcohol use disorder. (2013) (7)
Prevention of Depression and Bipolar Disorder (2005) (7)
Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. (2019) (7)
Nature and incidence of conditioned responses in a methadone population: a comparison of laboratory, clinic, and naturalistic settings. (1986) (6)
Utilizing benzodiazepines in clinical practice: an evidence-based discussion. (2004) (6)
Penn/VA center for studies of addiction (2009) (6)
Effectiveness Of Workplace Interventions (1994) (6)
The Role of Primary Care Physicians in Detection and Treatment of Adolescent Mental Health Problems (2005) (6)
Psychotherapy for cocaine dependence. (1992) (6)
The American Treatment System for Adolescent Substance Abuse: Formidable Challenges, Fundamental Revisions, and Mechanisms for Improvements (2005) (6)
Double-blind detoxification of methadone maintenance patients. (1975) (6)
Naltrexone: clinical data (2005) (6)
Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. (2017) (5)
New developments in addiction treatment. (2006) (5)
Naltrexone and Alcohol Dependence: Some Methodological Issues-Reply (1994) (5)
Rapid acquisition of conditioned responses to hydromorphone in detoxified heroin addicts. (1982) (5)
Treatment of alcoholism as a chronic disorder. (1994) (5)
Addiction versus dependence in pain management. Authors' reply (2006) (5)
Defining Youth Suicide (2005) (5)
COMMITTEE ON PREVENTION, DIAGNOSIS, TREATMENT AND MANAGEMENT OF SUBSTANCE USE DISORDERS IN THE U.S. ARMED FORCES (2013) (5)
The generality of benefits from alcohol and drug abuse treatments. (1981) (5)
Opioid antagonists: do they have a role in treatment programs? (1983) (5)
Opiate detoxification: what are the goals? (2005) (5)
Conditioning effects of narcotics in humans. (1978) (5)
Stroke in young women who use cocaine or amphetamines. (1998) (5)
Psychotherapy for opiate dependence. (1985) (5)
Developing and evaluating new treatments for alcoholism and cocaine dependence. (1992) (5)
Brief report: "spiders-No, puppies-Go", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. (2015) (5)
36. Brain imaging correlates of cue-induced cocaine craving (1996) (5)
Growth hormone-releasing activity in the hypothalami of kittens with lesions of the region of the paraventricular nuclei. (1968) (5)
Lack of Information in Naltrexone Study—Reply (2007) (5)
The Relationship of Alcohol Drinking and Endogenous Opioids: The Opioid Compensation Hypothesis (1992) (4)
Predictors of favorable outcome following naltrexone treatment. (1983) (4)
Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. (2018) (4)
Psychotherapeutic approaches in the treatment of drug abuse. (1984) (4)
The development of new medications for the treatment of alcoholism (1999) (4)
Internet gaming and addiction: a reply to King & Delfabbro. (2014) (4)
Patient selection for extended-release naltrexone among criminal justice-involved persons with opioid use disorder (2015) (4)
Update of naltrexone treatment. (1978) (4)
Desipramine treatment of cocaine abuse in methadone maintenance patients. (1989) (4)
Adolescent opioid abuse. (2005) (4)
A new medication for the worst addiction (2007) (4)
Persistent cognitive deficits attributed to substance abuse. (1993) (4)
The Role of Naltrexone in the Treatment of Opioid Dependence (1986) (4)
Naltrexone in federal probationers. (1989) (4)
Reply: Do Self-Reports Reliably Assess Abstinence in Cocaine-Dependent Patients? (2005) (4)
COMMITTEE ON DRUG USE IN THE WORKPLACE (1994) (4)
The effects of methadone on cortical and subcortical EEG in the rat. (1981) (4)
Developing medications to treat cocaine dependence: a new direction (1998) (4)
Follow-up of Vietnam veterans II. Social adjustment. (1980) (4)
Varenicline as maintenance therapy. (2007) (4)
The Impact of Modern Neuroscience on Treatment of Parolees: Ethical Considerations in Using Pharmacology to Prevent Addiction Relapse (2008) (4)
Usefulness of propoxyphene napsylate for maintenance treatment of narcotic addiction. (1979) (4)
The impact of the interview method on reported symptoms of narcotic addicts. (1980) (3)
Personality factors in methadone self-administration by heroin addicts. (1981) (3)
Addiction Severity Index (ASI-X) 1992 (1992) (3)
Clinical-behavioral observations of the long-term effects of drug abuse. (1990) (3)
Management of hostile, suspicious patients. Trifluoperazine versus haloperidol. (1974) (3)
Modafinil-Cocaine Interactions: Clinical Implications (2012) (3)
Can we design and replicate clinical trials with a multiple drug focus. (2003) (3)
Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision (2018) (3)
The neurobiology of drug addition (2002) (3)
Multivariate pattern analysis links drug use severity to distributed cortical hypoactivity during emotional inhibitory control in opioid use disorder (2021) (3)
Propoxyphene form maintenance treatment of narcotic addiction. (1981) (3)
NIDA's commitment to tackling drug abuse (2004) (3)
Best Practices in Prevention, Screening, Diagnosis, and Treatment of Substance Use Disorders (2013) (3)
Treatment of Depression and Bipolar Disorder (2005) (3)
Cocaine and Opioid Abuse/Dependence Disorders (2002) (3)
OR14-4EFFECTIVENESS OF EXTENDED-RELEASE NALTREXONE (XR-NTX) AMONG CRIMINAL JUSTICE-INVOLVED PERSONS WITH OPIOID USE DISORDERS (2014) (3)
Employee Assistance Programs (1994) (3)
Psychological and physiological response to hydromorphone: an opponent process view of addiction. (1982) (3)
Modification of treatment compliance as a function of contingent payment manipulations. (1979) (3)
A second varenicline trial. (2007) (3)
Abstinence treatments for opiate addicts: therapeutic community or naltrexone? (1984) (3)
Urine and Plasma Pharmacokinetics of Lofexidine after Oral Delivery in Opiate-Dependent Patients (2009) (3)
Clinical Implications of Cocaine-Induced Cortical Depression (2005) (2)
Anticraving agents for the treatment of addictive disorders (2004) (2)
No association between polymorphisms in the prostate apoptosis factor-4 gene and cocaine dependence (2006) (2)
Brain Development as a Vulnerability Factor in the Etiology of Substance Abuse and Addiction (2007) (2)
Modafinil and naltrexone for the treatment of comorbid cocaine and alcohol dependence (2015) (2)
Case-control association study of WLS variants in opioid and cocaine addicted populations (2013) (2)
Normalizing effects of modafinil on cocaine-induced sleep abnormalities. (2010) (2)
Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. (2018) (2)
Substance Abuse Treatment Research Center Philadelphia VA Medical Center and the University of Pennsylvania. (1988) (2)
Addiction Severity Index, 5th Ed. (ASI) 1980 (1980) (2)
Research Agenda for Schizophrenia (2005) (2)
Modern treatment of substance abuse. (1983) (2)
Catheterization of the lumbar subarachnoid space for long-term CSF collection in unanesthetized nonhuman primates (1986) (2)
Substance Use Disorder Workforce (2013) (2)
Medical education and treatment of addictive disorders. (2006) (1)
Etiology of Alcohol and Other Drug Use: An Overview of Potential Causes (1994) (1)
Changing Standards of Care for Substance Use Disorders (2013) (1)
Principles of the Pharmacotherapy of Addictive Disorders (2011) (1)
Drug Dependence as a Chronic Medical Illness—Reply (2001) (1)
[Commentary] modern treatment for prisoners. (2008) (1)
S-12-5 Basic and clinical research leading to the use of naltrexone in the treatment of alcoholism (1995) (1)
CSF endorphins in chronic opioid-dependent humans. (1986) (1)
Psychotherapy for substance abuse. (1986) (1)
Psychotherapy with Opioid-Dependent Patients (1998) (1)
Pharmacotherapy of Adolescent Substance Dependence (2004) (1)
Prevention of Substance Use Disorders (2005) (1)
Research Agenda for Depression and Bipolar Disorder (2005) (1)
Addressing Psychiatric Comorbidity: (496292006-008) (1991) (1)
Defining Substance Use Disorders (2005) (1)
A patient‐supported clinical trial (2010) (1)
“Destined for success”? Brain responses during drug cue exposure foretell clinical outcome in cocaine patients (2015) (1)
Stroke in young women who use cocaine or amphetamines. (1998) (1)
Group therapy of schizophrenia. (1977) (1)
Research Agenda for Anxiety Disorders (2005) (1)
157 MANAGING CHRONIC PAIN WITH OPIOIDS IN A PRIMARY CARE SETTING: ABERRANT BEHAVIORS SUGGESTIVE OF ADDICTION (2009) (1)
Prevention of Anxiety Disorders (2005) (1)
Preventing and treating substance use disorders in military personnel (2014) (1)
Epidemiological Evidence: The Dimensions of the Problem (1994) (1)
Treatment of addiction in the era of genomic medicine. (2007) (1)
Treatment of Eating Disorders (2005) (1)
The Persistent Challenge of Developing Addiction Pharmacotherapies. (2020) (1)
Discussion: using benzodiazepines in clinical practice. (2005) (1)
P.6.c.004 Association between the val158met polymorphism in the catechol-o-methyltransferase (comt) gene and cocaine dependence (2008) (1)
A hyper-connected and resilient small-world network in the cocaine-dependent brain (2015) (1)
Multimodality treatment of narcotic addiction: an overview. (1978) (1)
The Military Health System (2013) (0)
Observations concerning hypothalamic control of growth. (1970) (0)
Counseling level effects in methadone treatment (1991) (0)
Features of TRICARE and Related Purchased Care Plans (2013) (0)
Toward a rational selection of treatment for addiction (2007) (0)
HEROIN ADDICTION AND RELATED (2005) (0)
Opioid Addiction: Biology, Psychology, and Social Policy (2018) (0)
Opioid antagonist treatment modulates the brain responses to baby schema in opioid-dependent patients (2015) (0)
Frontal vs. limbic predictors of inhibitory success in addiction (2014) (0)
Medical and Nutritional Complications of Alcoholism: Mechanisms and Management (1994) (0)
Research Agenda for Substance Use Disorders (2005) (0)
Sex differences in functional connectivity during smoking cue exposure (2014) (0)
Clinical Applications of New Alcoholism Studies (1996) (0)
Introduction: Pharmacologic Treatment of Alcohol Abuse and Addiction (2001) (0)
The impact of sex on brain responses to smoking cues: a perfusion fMRI study (2013) (0)
Response to Dr. McAuliffe. (2018) (0)
Amygdala functional connectivity during craving inhibition attempts at baseline predicts craving and cocaine use (2014) (0)
Challenges to recruitment of cocaine-using women for a medication development trial (2014) (0)
Adapting treatment to patient problems. (2011) (0)
Continuity in Biological Treatment (1991) (0)
The Legal Environment of Drug Testing (1994) (0)
Receptors and endogenous ligands. Implications for addiction. (1992) (0)
Impact of Alcohol and Other Drug Use: Laboratory Studies (1994) (0)
Experimental analysis of narcotic use in humans. (1976) (0)
Introduction (2007) (0)
A 6-month follow-up of the integrated treatment for opiate addiction and HIV in Vietnam (2015) (0)
Preventive Interventions and Treatments for Suicidal Youth (2005) (0)
Levels of Care (2013) (0)
Addiction Severity Index 1980 (1995) (0)
Summary of Policy-Relevant Strategies for the Prevention of Alcohol-Related Problems (2013) (0)
Impact of Alcohol and Other Drug Use: Observational/Field Studies (1994) (0)
Lack of information in naltrexone study. Authors' reply (2007) (0)
Poorer pre-potent response inhibition in cocaine-dependent patients vs. healthy controls during an affect-congruent Go-NoGo task (2015) (0)
Drugs and youth: The challenge of today. (1975) (0)
Addiction medicine. (1997) (0)
Sex differences in brain responses to smoking cues: A perfusion fMRI study (2014) (0)
Effects of current smoking severity on brain gray matter volume in opioid use disorder – a voxel-based morphometry study (2023) (0)
The impact of Dutch and Flemish scientists on the progress of addiction medicine. (2013) (0)
Re: Enhancing Informed Consent for Research and Treatment ⋆ (2002) (0)
Detecting and Assessing Alcohol and Other Drug Use (1994) (0)
Switching gears: Shifts in reward function associated with age of onset of MJ use (2017) (0)
Preliminary results of polymerase chain reaction (PCR) testing of ELISA negative IVDUs in methadone treatment. (1990) (0)
Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction. (1980) (0)
Naltrexone: Factors Contributing to Retention in Treatment (1981) (0)
Barriers to Pharmacotherapy for Alcoholism after Liver Transplant (1999) (0)
The Social and Medical Aspects of Drug Abuse (2017) (0)
Evaluation of treatment for cocaine dependence.: (471562004-001) (1989) (0)
[Continuity in the neuroleptic treatment in patients with schizophrenia. Current data]. (1990) (0)
Prevention of Schizophrenia (2005) (0)
A higher hill to climb! Older cocaine-addicted patients viewing 500 ms cocaine cues have reduced activation of modulatory circuits and increased activation of motivational circuits (2015) (0)
group therapy for schizophrenia : a practical approach 3 (2005) (0)
Drs. Volkow and O'Brien Reply. (2008) (0)
Research Agenda for Youth Suicide Prevention (2005) (0)
Access to Care for Substance Use Disorders (2013) (0)
Workforce Standards for Substance Use Disorder (SUD) Care (2013) (0)
Universal Approaches to Youth Suicide Prevention (2005) (0)
CSF endorphins in chronic opioid-dependent humans.: (472392004-001) (1986) (0)
Cocaine abuse (1992) (0)
Alcohol and Drug Abuse in the Vietnam Veteran. (1976) (0)
The “little brain” steps up: Cerebellar activity during successful inhibition predicts treatment outcome in cocaine patients (2017) (0)
Sec. 596 of Public Law 111–84, October 28, 2009 (2013) (0)
Psychiatric symptoms in HIV test consenters and refusers. (1989) (0)
“Dangerous liaisons”: Heightened intra-limbic connectivity during subliminal cocaine cues is a relapse-vulnerable endophenotype (2015) (0)
Access Standards for TRICARE Prime Enrollees (2013) (0)
Update on behavioral treatments for substance abuse.: (473702004-001) (1988) (0)
Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence (2011) (0)
RAPID COMMUNICATION Absence of Naloxone Sensitivity in Obese Humans (2005) (0)
Evaluation of cognitive functioning of individuals with co-occurring opiate and amphetamine-type stimulants use disorders in Malaysia (2015) (0)
Commentary: Cynthia's Dilemma (2002) (0)
Applications of Human Behavioral Pharmacology to the Problems of Drug Addicts: A Brief Review (1984) (0)
Biosketches of Committee Members and Staff (2013) (0)
Evaluation Implications for Treatment , Insurance , and Outcomes Drug Dependence , a Chronic Medical Illness : (2000) (0)
Opioid Risk Tool - OUD (2021) (0)
NALTREXONE AND ALCOHOL DEPENDENCE : SOME METHODOLOGICAL ISSUES. AUTHORS' REPLY (1994) (0)
Heroin Add 7(2).indb (2005) (0)
Psychotherapeutic Approaches in the Treatment of Drug Abuse: (497002006-010) (1988) (0)
Neural responses to subliminally presented cannabis and other emotionally evocative cues in cannabis-dependent individuals (2013) (0)
Type of pre-treatment income and response to treatment in methadone maintenance. (1981) (0)
A Novel, Unexpected Treatment for Alcoholism (2012) (0)
Addiction and the medical profession (2005) (0)
Can we use cue-related brain responses to predict which cocaine patients will take more risks? (2015) (0)
Differential brain response to successful and failed response inhibition: Cocaine-dependent vs. healthy subjects (2015) (0)
When bigger isn’t better: Widespread brain activation during attempted inhibition of the response to 6 s cocaine video cues predicts poor drug use outcome (2017) (0)
Conference Abstracts:: ”Advances in Understanding the Addictive States” (1991) (0)
Treatment of Substance Use Disorders (2005) (0)
Preserved DNA from past clinical trials yields new information about a subtype of alcoholism (2008) (0)
TABLE 5-1, Best-Practice Domains and Recommendations of the National Institutes of Health's Behavior Change Consortium (2013) (0)
Baclofen, a GABA B Agonist, reduces risk-taking and reveals the relationship between brain responses to drug cues and risk-taking in cocaine-addicted patients (2014) (0)
Targeted Youth Suicide Prevention Programs (2005) (0)
Impact of Drug-Testing Programs on Productivity (1994) (0)
Translational Neuroscience: Addictive disorders (2012) (0)
Drug abuse programs raise QA concerns. (1989) (0)
S. 459 (111th): SUPPORT for Substance Use Disorders Act (2013) (0)
Prefrontal and striatal fMRI response predicts adherence to injectable extended-release naltrexone in opioid dependence (2015) (0)
Psychotherapy with Opioid-Dependent Patients November 01 , 1998 (2017) (0)
Opioid-Related Disorders: Antagonist Treatment (2014) (0)
Increased ventral striatum activation in response to heroin cues in heroin-dependent women after extended-release naltrexone injection (2015) (0)
MEETING REPORT Naltrexone in the Treatment of Alcoholism (1996) (0)
Understanding Substance Use Disorders in the Military (2013) (0)
Conditioning aspects of narcotics addiction (1974) (0)
Psychotherapy for substance abuse.: (469262004-001) (1988) (0)
Medical Diagnosis and Treatment of Alcoholism (1994) (0)
Scope of Alcohol and Other Durg Use (1994) (0)
Policies and Programs on Substance Use Disorders (2013) (0)

This paper list is powered by the following services:

Charles P. O’brien's Academic­Influence.com Rankings

Charles P. O’brien's Degrees

Why Is Charles P. O’brien Influential?

Charles P. O’brien's Published Works

Published Works

Charles P. O’brien's AcademicInfluence.com Rankings